Inhibikase Therapeutics Future Growth
Future criteria checks 2/6
Inhibikase Therapeutics is forecast to grow earnings and revenue by 25.2% and 73.2% per annum respectively while EPS is expected to grow by 43% per annum.
Key information
25.2%
Earnings growth rate
43.0%
EPS growth rate
Biotechs earnings growth | 20.7% |
Revenue growth rate | 73.2% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 20 Feb 2024 |
Recent future growth updates
Recent updates
Can Inhibikase Therapeutics (NASDAQ:IKT) Afford To Invest In Growth?
Jan 25Inhibikase stock rises 12% on FDA nod to start study of IkT-001Pro for leukemia
Aug 26Inhibikase Therapeutics GAAP EPS of -$0.18, revenue of $6.55M
Aug 12Will Inhibikase Therapeutics (NASDAQ:IKT) Spend Its Cash Wisely?
Aug 09Here's Why We're Watching Inhibikase Therapeutics' (NASDAQ:IKT) Cash Burn Situation
Apr 06Inhibikase Therapeutics prices stock offering at $3
Jun 16Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 9 | -25 | -28 | -22 | 2 |
12/31/2025 | N/A | -27 | -32 | -21 | 2 |
12/31/2024 | N/A | -22 | -24 | -19 | 2 |
12/31/2023 | 0 | -20 | -20 | -19 | 2 |
9/30/2023 | 0 | -19 | -18 | -18 | N/A |
6/30/2023 | 0 | -19 | -20 | -20 | N/A |
3/31/2023 | 0 | -18 | -20 | -19 | N/A |
12/31/2022 | 0 | -18 | -18 | -17 | N/A |
9/30/2022 | 0 | -19 | -18 | -18 | N/A |
6/30/2022 | 0 | -19 | -14 | -14 | N/A |
3/31/2022 | 2 | -17 | -14 | -14 | N/A |
12/31/2021 | 3 | -15 | -14 | -14 | N/A |
9/30/2021 | 3 | -11 | -11 | -11 | N/A |
6/30/2021 | 3 | -7 | -9 | -9 | N/A |
3/31/2021 | 2 | -5 | -5 | -5 | N/A |
12/31/2020 | 1 | -3 | -1 | -1 | N/A |
9/30/2020 | 1 | -2 | 0 | 0 | N/A |
6/30/2020 | 1 | -3 | 0 | 0 | N/A |
3/31/2020 | 1 | -5 | 0 | 0 | N/A |
12/31/2019 | 1 | -6 | 0 | 0 | N/A |
9/30/2019 | 2 | -7 | 1 | 1 | N/A |
3/31/2019 | 4 | -4 | 0 | 0 | N/A |
12/31/2018 | 4 | -2 | 1 | 1 | N/A |
9/30/2018 | 3 | -1 | 0 | 0 | N/A |
3/31/2018 | 3 | 0 | 0 | 0 | N/A |
12/31/2017 | 2 | 0 | 0 | 0 | N/A |
12/31/2016 | 1 | -1 | N/A | 0 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IKT is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: IKT is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: IKT is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: IKT's revenue (73.2% per year) is forecast to grow faster than the US market (8.2% per year).
High Growth Revenue: IKT's revenue (73.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if IKT's Return on Equity is forecast to be high in 3 years time